Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800616 | 1.00 | GAA (0.43) | GAACTSKACENFKB1NFKB2 | |
| SCHEMBL6802644 | 1.00 | GAA (0.43) | GAACTSKACENFKB1NFKB2 | |
| SCHEMBL10792822 | 0.91 | XIAP (0.42) | GAACTSKACENFKB1NFKB2 | |
| SCHEMBL10792831 | 0.91 | XIAP (0.42) | GAACTSKACENFKB1NFKB2 | |
| SCHEMBL6564073 | 0.88 | GAA (0.42) | GAACTSKNFKB1NFKB2RELA | |
| SCHEMBL10264443 | 0.88 | GAA (0.46) | GAACTSKNFKB1NFKB2RELA | |
| SCHEMBL325216 | 0.88 | GAA (0.46) | GAACTSKNFKB1NFKB2RELA | |
| SCHEMBL23297866 | 0.87 | GAA (0.41) | GAACTSKNFKB1NFKB2RELA | |
| SCHEMBL15113466 | 0.87 | GAA (0.41) | GAACTSKNFKB1NFKB2RELA | |
| SCHEMBL14265328 | 0.87 | GAA (0.41) | GAACTSKNFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101864-A1 | Chemical process | ATRAZENECA AB (SE) | 2004-05-27 | — | — | US | claimed |
| US-6248903-B1 | Process for the preparation of methyl (2s)-2-[(3r)-3-(n-{tert-butyloxycarbonyl 9-amino)-2-oxopyrrolidin-1-yl]propionate | ZENECA LIMITED (GB) | 2001-06-19 | — | — | US | claimed |
| EP-1076645-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO) -2-OXOPYRR OLIDIN-1-YL]PROPIONATE | AstraZeneca AB (SE) | 2001-02-21 | — | — | EP | claimed |
| WO-1999055669-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO)-2-OXOPYRROLIDIN-1-YL]PROPIONATE | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | claimed |
| US-20040101864-A1 | Chemical process | ATRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | disclosed |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2002-08-01 | — | — | US | disclosed |
| US-6355617-B1 | PEPTIDES, HYDROPHOBIC RESIDUES, AMINO ACIDS AND SEQUENCE | SYNGENTA LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |
| US-6248903-B1 | Process for the preparation of methyl (2s)-2-[(3r)-3-(n-{tert-butyloxycarbonyl 9-amino)-2-oxopyrrolidin-1-yl]propionate | ZENECA LIMITED (GB) | 2001-06-19 | — | — | US | disclosed |
| US-6248903-B1 | Process for the preparation of methyl (2s)-2-[(3r)-3-(n-{tert-butyloxycarbonyl 9-amino)-2-oxopyrrolidin-1-yl]propionate | ZENECA LIMITED (GB) | 2001-06-19 | — | — | US | disclosed |
| CN-1298387-A | Process for the preparation of methyl (2S)-2-[(3R)-3-CN-[tert-butyloxycarbonyl]-amino)-2-oxopyrrolidin-1-yL] propionate | ASTRA ZENECA LTD (SE) | 2001-06-06 | — | — | CN | disclosed |
| EP-1076645-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO) -2-OXOPYRR OLIDIN-1-YL]PROPIONATE | AstraZeneca AB (SE) | 2001-02-21 | — | — | EP | disclosed |
| US-6087336-A | ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | disclosed |
| WO-1999055669-A1 | PROCESS FOR THE PREPARATION OF METHYL(2S)-2-[(3R)-3-(N-[TERT-BUTYLOXYCARBONYL]-AMINO)-2-OXOPYRROLIDIN-1-YL]PROPIONATE | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103335-A1 | PEPTIDE DERIVATIVES | HLA-DRB1, MICA, TAP1 | GAA 3721/4885CTSK 3444/4885ACE 708/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | GAA 4428/4885CTSK 1972/4885ACE 2513/4885 |
| US-20040101864-A1 | Chemical process | ASS1, SRM, SRMS | GAA 2577/4885CTSK 4757/4885ACE 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.